Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FABP1 | P07148 | 1/20 | 0.42 |
| ▸ | FABP6 | P51161 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370120 | 0.98 | POLB (0.50) | POLBMAPTLMNADPP7HTT | |
| SCHEMBL3374310 | 0.89 | POLB (0.48) | POLBMAPTLMNAHTTHSD17B10 | |
| SCHEMBL25396462 | 0.79 | L3MBTL1 (0.53) | MAPTLMNADPP7HTTKMT2A | |
| SCHEMBL3796493 | 0.75 | POLB (0.54) | POLBMAPTLMNADPP7HTT | |
| SCHEMBL7772864 | 0.72 | DPP7 (0.55) | MAPTDPP7KMT2AMEN1TDP1 | |
| Hydrochloric Acid SCHEMBL8327254 | 0.72 | MAPT (0.80) | POLBMAPTLMNAHSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL8328364 | 0.72 | MAPT (0.80) | POLBMAPTLMNAHSD17B10KMT2A | |
| SCHEMBL6014539 | 0.72 | POLB (0.56) | POLBMAPTLMNADPP7HTT | |
| SCHEMBL9630573 | 0.70 | POLB (0.53) | POLBMAPTLMNAHTTHSD17B10 | |
| SCHEMBL6248215 | 0.69 | POLB (0.57) | POLBMAPTLMNADPP7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-2331492-A1 | METHOD FOR PREPARING THE ETHYL ESTER OF 4-[TRANS-4-[(PHENYLMETHYL)AMINO]CYCLOHEXYL]BENZOIC ACID AND THE HEMIFUMARATE SALT THEREOF | Sanofi-Aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020719-A1 | METHOD FOR PREPARING THE ETHYL ESTER OF 4-[TRANS-4-[(PHENYLMETHYL)AMINO]CYCLOHEXYL]BENZOIC ACID AND THE HEMIFUMARATE SALT THEREOF | SANOFIS-AVENTIS (FR) | 2010-02-25 | — | — | WO | disclosed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | POLB 2324/4885MAPT 2658/4885LMNA 2695/4885 |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | POLB 2324/4885MAPT 2658/4885LMNA 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.